Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.09
MYL's Cash to Debt is ranked lower than
90% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. MYL: 0.09 )
Ranked among companies with meaningful Cash to Debt only.
MYL' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.82 Max: 44.56
Current: 0.09
0.02
44.56
Equity to Asset 0.46
MYL's Equity to Asset is ranked lower than
73% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MYL: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
MYL' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.47 Max: 0.9
Current: 0.46
0.19
0.9
Interest Coverage 4.08
MYL's Interest Coverage is ranked lower than
86% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.03 vs. MYL: 4.08 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s Interest Coverage Range Over the Past 10 Years
Min: 0.83  Med: 3.59 Max: 9.19
Current: 4.08
0.83
9.19
F-Score: 7
Z-Score: 2.42
M-Score: -1.90
WACC vs ROIC
9.61%
8.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 15.85
MYL's Operating margin (%) is ranked higher than
72% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.51 vs. MYL: 15.85 )
Ranked among companies with meaningful Operating margin (%) only.
MYL' s Operating margin (%) Range Over the Past 10 Years
Min: 5.8  Med: 16.42 Max: 26.53
Current: 15.85
5.8
26.53
Net-margin (%) 9.34
MYL's Net-margin (%) is ranked higher than
62% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.44 vs. MYL: 9.34 )
Ranked among companies with meaningful Net-margin (%) only.
MYL' s Net-margin (%) Range Over the Past 10 Years
Min: -3.53  Med: 9.23 Max: 16.24
Current: 9.34
-3.53
16.24
ROE (%) 12.00
MYL's ROE (%) is ranked higher than
66% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. MYL: 12.00 )
Ranked among companies with meaningful ROE (%) only.
MYL' s ROE (%) Range Over the Past 10 Years
Min: -14.72  Med: 14.57 Max: 29.99
Current: 12
-14.72
29.99
ROA (%) 4.33
MYL's ROA (%) is ranked higher than
53% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. MYL: 4.33 )
Ranked among companies with meaningful ROA (%) only.
MYL' s ROA (%) Range Over the Past 10 Years
Min: -2.47  Med: 5.05 Max: 10.13
Current: 4.33
-2.47
10.13
ROC (Joel Greenblatt) (%) 22.88
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.81 vs. MYL: 22.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.9  Med: 35.11 Max: 47.2
Current: 22.88
17.9
47.2
Revenue Growth (3Y)(%) 11.60
MYL's Revenue Growth (3Y)(%) is ranked higher than
65% of the 581 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MYL: 11.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.1  Med: 15.55 Max: 54.5
Current: 11.6
-6.1
54.5
EBITDA Growth (3Y)(%) 11.30
MYL's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. MYL: 11.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -20  Med: 11.85 Max: 107
Current: 11.3
-20
107
EPS Growth (3Y)(%) 24.10
MYL's EPS Growth (3Y)(%) is ranked higher than
75% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. MYL: 24.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.1  Med: 12.20 Max: 110.4
Current: 24.1
-29.1
110.4
» MYL's 10-Y Financials

Financials (Next Earnings Date: 2016-02-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

MYL Guru Trades in Q1 2015

Tom Russo 5,850 sh (New)
Steven Cohen 253,300 sh (New)
Pioneer Investments 826,251 sh (+19.54%)
Vanguard Health Care Fund 15,891,898 sh (+5.68%)
Scott Black 187,570 sh (+3.18%)
Mario Gabelli 10,000 sh (unchged)
John Paulson 14,948,400 sh (unchged)
Paul Tudor Jones 125,000 sh (unchged)
Louis Moore Bacon Sold Out
Ray Dalio Sold Out
John Hussman Sold Out
First Eagle Investment 586,016 sh (-30.38%)
Paul Tudor Jones 109,447 sh (-56.94%)
Joel Greenblatt 16,021 sh (-97.62%)
» More
Q2 2015

MYL Guru Trades in Q2 2015

Jim Simons 548,006 sh (New)
Eric Mindich 1,456,404 sh (New)
Louis Moore Bacon 210,000 sh (New)
David Tepper 989,528 sh (New)
Kyle Bass 780,251 sh (New)
Larry Robbins 1,815,874 sh (New)
John Keeley 37,050 sh (New)
Steven Cohen 1,331,200 sh (+425.54%)
Mario Gabelli 33,250 sh (+232.50%)
John Paulson 21,913,061 sh (+46.59%)
Vanguard Health Care Fund 15,891,898 sh (unchged)
Tom Russo 5,850 sh (unchged)
George Soros 160,000 sh (unchged)
First Eagle Investment Sold Out
Joel Greenblatt Sold Out
Scott Black 185,573 sh (-1.06%)
Pioneer Investments 631,760 sh (-23.54%)
Paul Tudor Jones 12,766 sh (-88.34%)
» More
Q3 2015

MYL Guru Trades in Q3 2015

Jim Simons 1,716,741 sh (+213.27%)
Mario Gabelli 67,250 sh (+102.26%)
John Keeley 56,120 sh (+51.47%)
Vanguard Health Care Fund 23,262,875 sh (+46.38%)
Steven Cohen 1,000,000 sh (unchged)
John Paulson 21,913,061 sh (unchged)
Tom Russo 5,850 sh (unchged)
Eric Mindich Sold Out
Scott Black 180,575 sh (-2.69%)
Paul Tudor Jones 10,768 sh (-15.65%)
Pioneer Investments 365,302 sh (-42.18%)
Larry Robbins 934,006 sh (-48.56%)
David Tepper 470,071 sh (-52.50%)
Louis Moore Bacon 80,000 sh (-61.90%)
Steven Cohen 360,900 sh (-72.89%)
Kyle Bass 78,905 sh (-89.89%)
» More
Q4 2015

MYL Guru Trades in Q4 2015

Vanguard Health Care Fund 24,253,075 sh (+4.26%)
Mario Gabelli 26,450 sh (-60.67%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Mylan NV

Keeley Funds Comments on Mylan N.V. - Feb 03, 2016

The Fund’s largest contributor during the quarter was Mylan N.V (NASDAQ:MYL) which rose over 34 percent and added 84 basis points of return to the Fund. Shares were initially weak following its failed bid to merge with rival Perrigo (NYSE:PRGO). We viewed the failed bid as a positive as we were skeptical of the synergies between the two companies. We increased our exposure to the stock during the weakness as we believe the shares are very cheap on a valuation basis.



From the Keeley All Cap Value Fund 4th quarter 2015 shareholder letter.



Check out John Keeley latest stock trades

David Einhorn Comments on Mylan - Jan 19, 2016

We initiated a position in Mylan (NASDAQ:MYL), a global generic pharmaceuticals company. MYLshares fell 29% in the first three quarters of 2015 and over 45% from their mid-year highsafter generics rival Teva abandoned a hostile takeover bid for the company. During the fall,the market became overly focused on a series of overhangs including potential earningsdilution from a proposed and ultimately failed buyout of Perrigo (a private-label OTC business); corporate governance concerns including an unusual takeover-defense mechanism;and widespread unease about the pharmaceutical sector amidst scrutiny of specialty pharmaceutical manufacturers like Valeant.

We acknowledge eventual headwinds for the company’s branded EpiPen product, whichcould encounter competition from generics in late 2016. However, we see medium-termupside from a competitor recall, an announced share repurchase, and board review ofcorporate governance complaints. Ultimately, we expect MYL to earn close to $7 per share in2018, driven by a robust pipeline of respiratory, injectable and biologic drugs and by furthercapital deployment including share repurchases. We initiated our position at an average priceof $45.32, about 9x 2016 consensus EPS estimates. MYL shares ended the quarter at $54.07.

From David Einhorn (Trades, Portfolio)'s Green Light Capital fourth quarter 2015 shareholder letter.

Check out David Einhorn latest stock trades

Keeley Funds Comments on Mylan NV - Nov 03, 2015

The largest detractor during the quarter was in the health care sector after Mylan NV (NASDAQ:MYL) fell over 40 percent and cost the Fund 83 basis points in performance. The key development that pressured the stock was when rival TEVA Pharmaceutical (NYSE:TEVA) removed its takeover bid and instead acquired Allergan PLC’s (NYSE:AGN) generic business. Mylan remains interested in acquiring Perrigo (NYSE:PRGO) who prefers to remain independent. In addition, all of healthcare, and drug makers specifically, are seeing considerable selling pressure due to Valiant Pharmaceutical’s (NYSE:VRX) specialty pharmacy sales and Mylan does not use specialty pharmacies. Lastly, political rhetoric about price controls in health care is being bandied about by the Democratic frontrunner and those comments have had a negative impact on the entire industry.





From the Keeley All-Cap Value Fund commentary on third quarter 2015.



Check out John Keeley latest stock trades

Vanguard Health Care Fund Comments on Mylan NV - Mar 27, 2015

We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Mylan NV

Keeley Funds Comments on Mylan N.V. Guru stock highlight
The Fund’s largest contributor during the quarter was Mylan N.V (NASDAQ:MYL) which rose over 34 percent and added 84 basis points of return to the Fund. Shares were initially weak following its failed bid to merge with rival Perrigo (NYSE:PRGO). We viewed the failed bid as a positive as we were skeptical of the synergies between the two companies. We increased our exposure to the stock during the weakness as we believe the shares are very cheap on a valuation basis. Read more...
David Einhorn Comments on Mylan Guru stock highlight
We initiated a position in Mylan (NASDAQ:MYL), a global generic pharmaceuticals company. MYLshares fell 29% in the first three quarters of 2015 and over 45% from their mid-year highsafter generics rival Teva abandoned a hostile takeover bid for the company. During the fall,the market became overly focused on a series of overhangs including potential earningsdilution from a proposed and ultimately failed buyout of Perrigo (a private-label OTC business); corporate governance concerns including an unusual takeover-defense mechanism;and widespread unease about the pharmaceutical sector amidst scrutiny of specialty pharmaceutical manufacturers like Valeant. Read more...
Vanguard Raises Stakes in Biogen, Mylan, Merck Fund buys no new stakes in 3rd quarter
As its name suggests, Vanguard Health Care Fund (Trades, Portfolio) is almost exclusively interested in health care companies. It bought no new stakes in the third quarter, but it did make additions to several existing stakes. Read more...
Keeley Funds Comments on Mylan NV Guru stock highlight.
The largest detractor during the quarter was in the health care sector after Mylan NV (NASDAQ:MYL) fell over 40 percent and cost the Fund 83 basis points in performance. The key development that pressured the stock was when rival TEVA Pharmaceutical (NYSE:TEVA) removed its takeover bid and instead acquired Allergan PLC’s (NYSE:AGN) generic business. Mylan remains interested in acquiring Perrigo (NYSE:PRGO) who prefers to remain independent. In addition, all of healthcare, and drug makers specifically, are seeing considerable selling pressure due to Valiant Pharmaceutical’s (NYSE:VRX) specialty pharmacy sales and Mylan does not use specialty pharmacies. Lastly, political rhetoric about price controls in health care is being bandied about by the Democratic frontrunner and those comments have had a negative Read more...
Alan Fournier Sells Nine Stakes in Second Quarter Divestitures are the most Fournier has recorded in years
Alan Fournier (Trades, Portfolio) founded Pennant Capital Management in 2001 and manages Pennant Master Fund, Pennant Windward Master Fund, Broadway Gate Master Fund Ltd.,and Pennant General Partner LLC. Today Pennant Capital Management is worth around $4 billion. Read more...
Sequoia Fund Comments on Perrigo Guru stock highlight
Saatvik Agarwal: Read more...
Kyle Bass Focuses on Fuel, Pharmaceutical Stocks in Second Quarter
If there was a theme to Kyle Bass (Trades, Portfolio)’ investment activity in the second quarter, the founder of Dallas-based Hayman Capital Management L.P., displayed an interest in fuel and pharmaceutical stocks. Not all of Bass’ transactions fit neatly into that category, of course, but many did, including most of the largest ones. Read more...
Vanguard Health Care Fund Comments on Mylan NV
We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 29.36
MYL's P/E(ttm) is ranked lower than
55% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.86 vs. MYL: 29.36 )
Ranked among companies with meaningful P/E(ttm) only.
MYL' s P/E(ttm) Range Over the Past 10 Years
Min: 7.05  Med: 24.92 Max: 112.56
Current: 29.36
7.05
112.56
Forward P/E 9.57
MYL's Forward P/E is ranked higher than
85% of the 419 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.50 vs. MYL: 9.57 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 29.36
MYL's PE(NRI) is ranked lower than
51% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.45 vs. MYL: 29.36 )
Ranked among companies with meaningful PE(NRI) only.
MYL' s PE(NRI) Range Over the Past 10 Years
Min: 7.05  Med: 25.28 Max: 200.11
Current: 29.36
7.05
200.11
P/B 2.56
MYL's P/B is ranked higher than
50% of the 928 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.54 vs. MYL: 2.56 )
Ranked among companies with meaningful P/B only.
MYL' s P/B Range Over the Past 10 Years
Min: 0.64  Med: 2.67 Max: 7.02
Current: 2.56
0.64
7.02
P/S 2.68
MYL's P/S is ranked lower than
52% of the 929 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.60 vs. MYL: 2.68 )
Ranked among companies with meaningful P/S only.
MYL' s P/S Range Over the Past 10 Years
Min: 0.41  Med: 1.83 Max: 4.61
Current: 2.68
0.41
4.61
PFCF 40.09
MYL's PFCF is ranked lower than
60% of the 485 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.85 vs. MYL: 40.09 )
Ranked among companies with meaningful PFCF only.
MYL' s PFCF Range Over the Past 10 Years
Min: 8.81  Med: 19.60 Max: 151.31
Current: 40.09
8.81
151.31
POCF 16.95
MYL's POCF is ranked higher than
64% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.68 vs. MYL: 16.95 )
Ranked among companies with meaningful POCF only.
MYL' s POCF Range Over the Past 10 Years
Min: 6.09  Med: 12.68 Max: 40.56
Current: 16.95
6.09
40.56
EV-to-EBIT 23.57
MYL's EV-to-EBIT is ranked lower than
61% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.42 vs. MYL: 23.57 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.7  Med: 17.30 Max: 36.9
Current: 23.57
-10.7
36.9
EV-to-EBITDA 14.28
MYL's EV-to-EBITDA is ranked higher than
58% of the 852 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. MYL: 14.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: 11.00 Max: 23.3
Current: 14.28
-17.7
23.3
PEG 3.63
MYL's PEG is ranked lower than
64% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. MYL: 3.63 )
Ranked among companies with meaningful PEG only.
MYL' s PEG Range Over the Past 10 Years
Min: 0.59  Med: 2.54 Max: 11.64
Current: 3.63
0.59
11.64
Shiller P/E 88.82
MYL's Shiller P/E is ranked lower than
75% of the 166 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.90 vs. MYL: 88.82 )
Ranked among companies with meaningful Shiller P/E only.
MYL' s Shiller P/E Range Over the Past 10 Years
Min: 14.33  Med: 66.26 Max: 152.12
Current: 88.82
14.33
152.12
Current Ratio 1.76
MYL's Current Ratio is ranked lower than
61% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. MYL: 1.76 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 1.28  Med: 3.23 Max: 8.49
Current: 1.76
1.28
8.49
Quick Ratio 1.23
MYL's Quick Ratio is ranked lower than
63% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. MYL: 1.23 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.69 Max: 6.76
Current: 1.23
0.85
6.76
Days Inventory 136.28
MYL's Days Inventory is ranked lower than
60% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.42 vs. MYL: 136.28 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 140.60 Max: 175.9
Current: 136.28
88.95
175.9
Days Sales Outstanding 118.03
MYL's Days Sales Outstanding is ranked lower than
76% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.67 vs. MYL: 118.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.32  Med: 84.21 Max: 107.26
Current: 118.03
70.32
107.26
Days Payable 92.11
MYL's Days Payable is ranked higher than
63% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. MYL: 92.11 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 44.56  Med: 70.84 Max: 101.21
Current: 92.11
44.56
101.21

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.72
MYL's Price/Projected FCF is ranked higher than
65% of the 523 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. MYL: 1.72 )
Ranked among companies with meaningful Price/Projected FCF only.
MYL' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.39 Max: 2.61
Current: 1.72
0.62
2.61
Price/DCF (Earnings Based) 3.75
MYL's Price/DCF (Earnings Based) is ranked lower than
73% of the 124 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.55 vs. MYL: 3.75 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.46
MYL's Price/Median PS Value is ranked lower than
67% of the 899 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. MYL: 1.46 )
Ranked among companies with meaningful Price/Median PS Value only.
MYL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 1.92 Max: 3.53
Current: 1.46
0.36
3.53
Price/Peter Lynch Fair Value 3.06
MYL's Price/Peter Lynch Fair Value is ranked lower than
61% of the 244 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.72 vs. MYL: 3.06 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYL' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.67  Med: 1.60 Max: 10.2
Current: 3.06
0.67
10.2
Earnings Yield (Greenblatt) (%) 4.31
MYL's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 720 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MYL: 4.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.7  Med: 5.40 Max: 19
Current: 4.31
2.7
19
Forward Rate of Return (Yacktman) (%) 12.62
MYL's Forward Rate of Return (Yacktman) (%) is ranked higher than
65% of the 318 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.62 vs. MYL: 12.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYL' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.6  Med: 6.30 Max: 38
Current: 12.62
3.6
38

More Statistics

Revenue(Mil) $9023
EPS $ 1.75
Beta1.27
Short Percentage of Float15.09%
52-Week Range $37.59 - 76.69
Shares Outstanding(Mil)491.75

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 9,650 10,823 11,300 11,918
EPS($) 4.31 4.99 5.37 5.62
EPS without NRI($) 4.31 4.99 5.37 5.62

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:6MY.Germany, MYL1.Switzerland, 0R5P.UK,
Mylan NV was incorporated in Netherlands on July 7, 2014. The Company along with its subsidiaries is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. It also operates a research and development network that delivers a robust product pipeline. The Company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as active pharmaceutical ingredients. The generic pharmaceutical business is conducted in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Specialty segment engages in the development and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and has also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Keeley Funds Comments on Mylan N.V. Feb 03 2016 
KEELEY All Cap Value Fund Commentary - 4th Quarter 2015 Feb 03 2016 
David Einhorn Comments on Mylan Jan 19 2016 
Glenview's Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
Health Care Investor Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
John Paulson Keeps Gold, Buys Drug Manufacturers Nov 17 2015 
Vanguard Raises Stakes in Biogen, Mylan, Merck Nov 15 2015 
Keeley Funds Comments on Mylan NV Nov 03 2015 
Vanguard Health Care Fund Buys Biogen and Mylan, Cuts Pfizer Nov 02 2015 
Alan Fournier Sells Nine Stakes in Second Quarter Sep 12 2015 

More From Other Websites
The Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, United Therapeutics and INSYS... Feb 03 2016
4 Top-Ranked Biotech Stocks on Sale Feb 02 2016
Stock Watchout on Drugs - Generic -- Mylan, Neurocrine Biosciences, Horizon Pharma, and Zoetis Feb 02 2016
Mylan’s PE Ratio of 10.1x Is Lower Than Its Peer Ratios Feb 01 2016
[$$] Barron's 2016 Roundtable, Part 3: 12 Stock Picks Jan 30 2016
The Majority of Brokers Recommend a “Buy” for Mylan Jan 28 2016
Analysts Expect Mylan’s Growth to Be at 29.7% for 4Q15 Jan 28 2016
Mylan NV breached its 50 day moving average in a Bullish Manner : January 25, 2016 Jan 25 2016
[$$] Part 2 of the Barron's 2016 Roundtable: 31 Savvy Investment Ideas Jan 23 2016
Mylan to Report Fourth Quarter and Full Year 2015 Financial Results on Feb. 10, 2016 Jan 21 2016
David Einhorn Feels Mylan's Pain Jan 20 2016
David Einhorn and the Terrible, Horrible, No Good, Very Bad 2015 Jan 20 2016
David Einhorn's New Long Position In Mylan Jan 19 2016
Highlights From Greenlight’s Q4 Letter: Micron Is Out & Two New Positions Jan 19 2016
A Look Into David Einhorn's Q4 Letter To Greenlight Investors Jan 19 2016
Mylan Launches Generic Felbatol® Tablets Jan 19 2016
Mylan CEO: Don’t think the answer is price controls on drugs Jan 12 2016
Goldman's top 25 Tactical Option Trades ahead of Earnings Jan 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK